A recent study has revealed that a new type of cholesterol-lowering drug can protect patients from heart attacks and strokes, without the risks associated with statins. One of the most popular statins, Lipitor, has been prescribed to more than 29 million people. Patients have cited... Read More

Coordination of Lipitor diabetes lawsuits continues to move forward in federal court in South Carolina. The judge overseeing the multidistrict litigation or MDL concerning Lipitor allegations has scheduled the initial trial to begin in October 2015. This early trial, also known as a bellwether trial,... Read More

The prescription drug Lipitor (atorvastatin calcium) has been prescribed in thousands of patients across the United States for treatment of elevated LDL-cholesterol. Despite its position as the number one selling drug of all time, Lipitor is not without drawbacks – including the increased risk of... Read More

The first Lipitor diabetes lawsuit is set to begin on or after July 1, 2015, according to guidelines issued by the presiding judge in the multidistrict litigation (MDL) consolidated in the U.S. District Court of the District of South Carolina. In the case management order... Read More

A generic Lipitor recall has been issued by India’s largest drugmaker, Ranbaxy Laboratories, Ltd. More than 64,000 bottles of the generic cholesterol-lowering drug have been recalled, following regulatory concerns on the manufacturing quality of the drug, after a dosage error was identified. According to the... Read More

The U.S. Judicial Panel on Multidistrict Litigation has ruled that all federal Lipitor diabetes lawsuits should be transferred to U.S. District Court for the District of South Carolina for coordinated pretrial proceedings. The order was handed down on February 18, after it was determined that... Read More

In August 2013, a Lipitor lawsuit was filed on behalf of Health Support Awareness, Inc., against Pfizer. The complaint is a whistleblower lawsuit, also known as a qui tam complaint. The plaintiffs, known as the relators, allege that the defendants engaged in deceptive marketing practices... Read More

Cholesterol lowering drugs, known as statins, and their potential side effects have been the topic of concern among health care practitioners, the FDA and consumers, as emerging research finds more evidence of serious risks.  In 2012, the FDA announced updates on statin risks for Pfizer’s... Read More